Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 coactivation

9 Dec 2024

Abstract excerpt

ABSTRACT: Initial clinical trials with drugs targeting epigenetic modulators, such as bromodomain and extraterminal protein (BET) inhibitors, demonstrate modest results in acute myeloid leukemia (AML). A major reason for this involves an increased transcriptional plasticity within AML, which allows the cells to escape therapeutic pressure. In this study, we investigated the immediate epigenetic and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histone Deacetylase Inhibitors Research
Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39651888
DOI: 10.1182/blood.2022019306

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 coactivationPMID 39651888Read ↗

Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 co-activationSemantic proximity Read ↗

Acute Myeloid Leukemia Relapse after Bromodomain Inhibitor Treatment or Chemotherapy is Characterized by Myc-Ras Transcriptional RemodelingSemantic proximity Read ↗

Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML)Semantic proximity Read ↗

The transcriptional regulatory circuit as a driver and therapeutic target in CML blast crisisSemantic proximity Read ↗

Convergent organization of aberrant MYB complex controls oncogenic gene expression in acute myeloid leukemiaSemantic proximity Read ↗

Exploiting an Epigenetic Resistance Mechanism to PI3 Kinase Inhibition in Leukemic Stem CellsSemantic proximity Read ↗

p300 suppresses the transition of myelodysplastic syndromes to acute myeloid leukemia.Semantic proximity Read ↗

Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical ApplicationsSemantic proximity Read ↗

A Histone Acetyltransferase p300 Inhibitor C646 Induces Cell Cycle Arrest and Apoptosis Selectively in AML1-ETO-Positive AML CellsSemantic proximity Read ↗

Convergent organization of aberrant MYB complex controls oncogenic gene expression in acute myeloid leukemiaSemantic proximity Read ↗

An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia.Semantic proximity Read ↗

Ezh2 loss propagates hypermethylation at T cell differentiation–regulating genes to promote leukemic transformationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.